UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_______________
 
FORM 8-K
_______________
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): July 31, 2011
 
_______________
 
Biostem U.S. Corporation
(Exact Name of Registrant as Specified in Its Charter)
 
_______________
 
Nevada
 
333-158560
 
80-0324801
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

1266 Turner Street
Clearwater, FL 33756
(Address of Principal Executive Offices) (Zip Code)
 
727-446-5000
(Registrant’s Telephone Number, Including Area Code)
 
EQUINOX INTERNATIONAL, INC.
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 


 
 
 

 

ITEM 1.02. TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.
 
See Item 5.02 below.
 
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGMENTS OF CERTAIN OFFICERS
 
Effective July 31, 2011, Ron Sloma resigned a director and Chief Financial Officer of the Company, his employment agreement with the Company was terminated, and John Satino, the Company’s Vice President, was appointed as interim Chief Financial Officer.
 
 
 
 
 
2

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
Biostem U.S. Corporation
 
       
Dated: August 1, 2011
By:
/s/ Dwight C. Brunoehler  
    Dwight C. Brunoehler, Chief Executive Officer  
       
       
 
 
 
 
3